Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ARC 1779

Known as: ARC-1779, ARC1779 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Blockade of hyperactive von Willebrand factor (VWF) by ARC1779 blunted the platelet drop induced by desmopressin in patients with… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2011
2011
Thrombotic thrombocytopenic purpura (TTP) can cause severe organ damage due to enhanced platelet aggregation by ultra-large von… Expand
Is this relevant?
Review
2010
Review
2010
Platelet inhibitors are the mainstay treatment for patients with vascular diseases. The current 'gold standard' antiplatelet… Expand
Is this relevant?
2010
2010
Desmopressin aggravates thrombocytopenia in type 2B von Willebrand disease (VWF type 2B) by release of large and hyper-adhesive… Expand
Is this relevant?
2010
2010
BACKGROUND In thrombotic thrombocytopenic purpura (TTP), ultralarge von Willebrand factor (VWF) multimers bind platelet (PLT… Expand
Is this relevant?
2009
2009
BACKGROUND Plasma exchange is the main therapy for thrombotic thrombocytopenic purpura (TTP). No treatments other than plasma… Expand
Is this relevant?
2009
2009
ARC1779 is an aptamer, which blocks binding of the von Willebrand Factor (VWF) A1 domain to platelet GPIb receptors. VWF is… Expand
Is this relevant?
2007
2007
Background—ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?